Evidence map›Paper›PMID 25537519›Full record

ReviewOncotarget2014

Classification of current anticancer immunotherapies.

Lorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean-Pierre Abastado, Patrizia Agostinis and 78 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03922776 (Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy), which is not on this map. Cited by 231 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03922776 naterminatednot on this mapstarted 2019, after this paper: background citation

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy

TypeinterventionalSponsorCentre Oscar LambretRan2019 to 2024Enrolled36ConditionsOvarian Cancer Stage IIIC, Fallopian Tube Cancer Stage IIIC, Fallopian Tube Cancer Stage IV, Ovarian Cancer Stage IVArmsBlood sample collection
3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Bacterial Outer Membrane Vesicle (OMV)-Encapsulated TiONanomaterials (Basel, Switzerland) · 2024
    Article

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

88 authors.

Lorenzo GalluzziEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
Erika VacchelliEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
José-Manuel Bravo-San PedroEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
Aitziber BuquéEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
Laura SenovillaEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France.
Elisa Elena BaraccoEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
Norma BloyEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
Francesca CastoldiEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France. Sotio a.c., Prague, Czech Republic.
Jean-Pierre AbastadoPole d'innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France.
Patrizia AgostinisCell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium.
Ron N ApteThe Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Fernando ArandaEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Maha AyyoubINSERM, U1102, Saint Herblain, France. Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Philipp BeckhoveTranslational Immunology Division, German Cancer Research Center, Heidelberg, Germany.
Jean-Yves BlayEquipe 11, Centre Léon Bérard (CLR), Lyon, France. Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France.
Laura BracciDept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Anne CaignardINSERM, U1160, Paris, France. Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France.
Chiara CastelliUnit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
Federica CavalloMolecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Estaban CelisCancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA.
Vincenzo CerundoloMRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Aled ClaytonInstitute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK. Velindre Cancer Centre, Cardiff, UK.
Mario P ColomboUnit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
Lisa CoussensKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Madhav V DhodapkarSect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA.
Alexander M EggermontGustave Roussy Cancer Campus, Villejuif, France.
Douglas T FearonCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Wolf H FridmanINSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. Equipe 13, Centre de Recherche des Cordeliers, Paris, France.
Jitka FučíkováSotio a.c., Prague, Czech Republic. Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
Dmitry I GabrilovichDept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jérôme GalonINSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France.
Abhishek GargCell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium.
François GhiringhelliINSERM, UMR866, Dijon, France. Centre Georges François Leclerc, Dijon, France. Université de Bourgogne, Dijon, France.
Giuseppe GiacconeCenter for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Eli GilboaDept. of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
Sacha GnjaticSect. of Hematology/Oncology, Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Axel HoosGlaxo Smith Kline, Cancer Immunotherapy Consortium, Collegeville, PA, USA.
Anne HosmalinUniversité Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. INSERM, U1016, Paris, France. CNRS, UMR8104, Paris, France. Hôpital Cochin, AP-HP, Paris, France.
Dirk JägerNational Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany.
Pawel KalinskiDept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA. Dept. of Immunology and Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA.
Klas KärreDept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Oliver KeppEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
Rolf KiesslingDept. of Oncology, Karolinska Institute Hospital, Stockholm, Sweden.
John M KirkwoodUniversity of Pittsburgh Cancer Institute Laboratory, Pittsburgh, PA, USA.
Eva KleinDept. of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Alexander KnuthNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Claire E LewisAcademic Unit of Inflammation and Tumour Targeting, Dept. of Oncology, University of Sheffield Medical School, Sheffield, UK.
Roland LiblauINSERM, UMR1043, Toulouse, France. CNRS, UMR5282, Toulouse, France. Laboratoire d'Immunologie, CHU Toulouse, Université Toulouse II, Toulouse, France.
Michael T LotzeDept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA.
Enrico LugliUnit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy.
Jean-Pierre MachDept. of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Fabrizio MatteiDept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Domenico MavilioUnit of Clinical and Experimental Immunology, Humanitas Clinical and Research Institute, Rozzano, Italy. Dept. of Medical Biotechnologies and Translational Medicine, University of Milan, Rozzano, Italy.
Ignacio MeleroDept. of Immunology, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain. Dept. of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Cornelis J MeliefISA Therapeutics, Leiden, The Netherlands. Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Elizabeth A MittendorfResearch Dept. of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Lorenzo MorettaIstituto Giannina Gaslini, Genova, Italy.
Adekunke OdunsiCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA.
Hideho OkadaDept. of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Anna Karolina PaluckaThe Jackson Laboratory for Genomics Medicine, Farmington, CT, USA.
Marcus E PeterDiv. of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Kenneth J PientaThe James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Angel PorgadorThe Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
George C PrendergastLankenau Institute for Medical Research, Wynnewood, PA, USA. Dept. of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College, Philadelphia, PA, USA. Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Gabriel A RabinovichLaboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina.
Nicholas P RestifoNational Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Naiyer RizviMemorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
Catherine Sautès-FridmanINSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. Equipe 13, Centre de Recherche des Cordeliers, Paris, France.
Hans SchreiberDept. of Pathology, The Cancer Research Center, The University of Chicago, Chicago, IL, USA.
Barbara SeligerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Hiroshi ShikuDept. of Immuno-GeneTherapy, Mie University Graduate School of Medicine, Tsu, Japan.
Bruno Silva-SantosInstituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal.
Mark J SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia.
Daniel E SpeiserDept. of Oncology, University of Lausanne, Lausanne, Switzerland. Ludwig Cancer Research Center, Lausanne, Switzerland.
Radek SpisekSotio a.c., Prague, Czech Republic. Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
Pramod K SrivastavaDept. of Immunology, University of Connecticut School of Medicine, Farmington, CT, USA. Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA.
James E TalmadgeLaboratory of Transplantation Immunology, Dept. of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Eric TartourUniversité Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. INSERM, U970, Paris, France. Paris-Cardiovascular Research Center (PARCC), Paris, France. Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.
Sjoerd H Van Der BurgDept. of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Benoît J Van Den EyndeLudwig Institute for Cancer Research, Brussels, Belgium. de Duve Institute, Brussels, Belgium. Université Catholique de Louvain, Brussels, Belgium.
Richard VileDept. of Molecular Medicine and Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Hermann WagnerInstitute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany.
Jeffrey S WeberDonald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, FL, USA.
Theresa L WhitesideUniversity of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jedd D WolchokDept. of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA. Weill Cornell Medical College, New York, NY, USA.
Laurence ZitvogelGustave Roussy Cancer Campus, Villejuif, France. INSERM, U1015, Villejuif, France. Centre d'Investigation Clinique Biothérapie 507 (CICBT507), Gustave Roussy Cancer Campus, Villejuif, France.
Weiping ZouUniversity of Michigan, School of Medicine, Ann Arbor, MI, USA.
Guido KroemerEquipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Building on the success of the adoptive immunotherapy of cancerZIABC010763 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2020
$25.0M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
IDO Inhibitors for Combinatorial Cancer TherapyR01CA109542 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2005 to 2015
$2.0M
NCATS NIH HHS UL1 TR000430NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA109542
6 · The paper itself

Abstract

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.

Indexed as

AnimalsHumansImmunotherapyNeoplasms

Identifiers

PMID25537519
PMCPMC4350348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.